- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06868004
Holistic Nursing Benefits Cognitive and Psychiatric Symptoms in Alzheimer's Patients
Positive Impact of Holistic Nursing on Cognitive Impairment and Psychiatric Symptoms in Patients with Alzheimer's Disease
This clinical study aims to evaluate the effects of a holistic nursing (HN) intervention on cognitive function, psychological well-being, and overall health outcomes in patients with Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral changes, significantly impacting patients' quality of life and increasing the burden on caregivers. Conventional treatment primarily involves pharmacological interventions, but non-pharmacological approaches, such as specialized nursing care, have shown potential in improving patient outcomes.
This study prospectively enrolled 105 AD patients admitted to our hospital between January 2023 and January 2024. Patients were divided into two groups based on admission periods: the control group (n=58) received standard care, while the observation group (n=47) received HN in addition to standard care. The HN intervention was implemented based on established guidelines for older adults with cognitive impairment and consisted of five key components: psychological support, cognitive stimulation, memory enhancement, self-care training, and environmental optimization.
The study assessed cognitive function, psychiatric symptoms, anxiety, and depression levels before and after the intervention using validated scales, including the Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Montreal Cognitive Assessment (MoCA), and Self-rating Anxiety/Depression Scales (SAS/SDS). Additionally, blood biomarkers related to neurological function, such as dopamine, acetylcholine, serotonin, γ-aminobutyric acid, S100β, homocysteine, and interleukin-1β, were measured.
Patient compliance, safety outcomes, and family satisfaction with the nursing intervention were also evaluated. The findings of this study may provide evidence supporting the integration of HN as a complementary approach in AD management, potentially improving cognitive function, reducing psychiatric symptoms, and enhancing overall patient well-being.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Liaoning
-
Jinzhou, Liaoning, China
- The First Affiliated Hospital of Jinzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with Alzheimer's Disease (AD) according to clinical and neuroimaging evidence.
- Aged between 60 to 80 years.
- Mild-to-moderate disease severity, with a Mini-Mental State Examination (MMSE) score ranging from 10 to 24.
- Adequate cognitive and functional capacity to complete questionnaires and follow the intervention protocol.
- Ability to communicate and comprehend instructions.
- Availability of comprehensive medical records.
- Informed consent obtained from the patient or their legal guardian.
Exclusion Criteria:
- History of intracranial surgery or major brain trauma.
- Coexisting psychiatric disorders or severe mental illnesses.
- Significant visual, auditory, language, or motor impairments that would hinder participation in the study.
- Severe organ dysfunction that could interfere with study participation or safety.
- Comorbid autoimmune diseases or severe malignancies.
- Participants who have received experimental treatments or clinical trials within the last 3 months.
- Pregnant or breastfeeding women.
- Individuals with a history of substance abuse or dependency.
- Participants with other medical conditions that, in the opinion of the investigator, would compromise participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Group
|
|
|
Experimental: Observation Group
|
The intervention in this study is based on Holistic Nursing (HN) for patients with Alzheimer's Disease (AD).
It involves a comprehensive approach including psychological support, cognitive rehabilitation, memory enhancement, self-care training, and environmental modifications.
Psychological interventions focus on personalized communication and emotional support, aiming to reduce negative emotions and improve trust in the healthcare team.
Cognitive interventions include activities like painting, card recognition, and storytelling to enhance cognitive function.
Memory interventions use personalized memory aids, and self-care interventions aim to improve daily living skills.
The ward environment is adjusted to promote safety and comfort.
This multi-faceted approach is designed to improve cognitive function, self-care abilities, and emotional well-being in AD patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cognitive Function Assessed by MMSE
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
The improvement in cognitive function will be measured using the Mini-Mental State Examination (MMSE) score.
Cognitive changes will be evaluated pre- and post-intervention to assess the effectiveness of the Holistic Nursing intervention.
|
Baseline (before intervention) and after 6 months of intervention.
|
|
Change in Cognitive Function Assessed by MoCA
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
The improvement in cognitive function will be measured using the Montreal Cognitive Assessment (MoCA) score.
Cognitive changes will be evaluated pre- and post-intervention to assess the effectiveness of the Holistic Nursing intervention.
|
Baseline (before intervention) and after 6 months of intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Psychiatric Symptoms Assessed by NPI
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
Reduction in psychiatric symptoms will be measured using the Neuropsychiatric Inventory (NPI) score.
Lower scores will indicate improvements in symptoms such as anxiety, depression, and agitation.
|
Baseline (before intervention) and after 6 months of intervention.
|
|
Change in Anxiety Levels (SAS Score)
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
Anxiety levels will be measured using the Self-Rating Anxiety Scale (SAS).
The SAS score ranges from 20 to 80, with higher scores indicating greater anxiety severity.
A reduction in scores post-intervention will indicate an improvement in anxiety symptoms.
|
Baseline (before intervention) and after 6 months of intervention.
|
|
Medication Adherence
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
Patient adherence to prescribed medication will be measured using the Morisky Medication Adherence Scale-8 (MMAS-8).
The MMAS-8 score ranges from 0 to 8, with higher scores indicating better adherence to medication regimens.
|
Baseline (before intervention) and after 6 months of intervention.
|
|
Family Satisfaction
Time Frame: At discharge (approximately within 24 hours of patient discharge).
|
Family satisfaction with nursing care and interventions will be assessed using a validated nursing satisfaction questionnaire.
The questionnaire includes a Likert scale ranging from 1 to 5, where higher scores indicate greater satisfaction.
The overall satisfaction rate will provide insights into the perceived effectiveness of the intervention from the family's perspective.
|
At discharge (approximately within 24 hours of patient discharge).
|
|
Change in Cognitive Function Related to Psychiatric Symptoms Assessed by ADAS-cog
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
Cognitive changes associated with psychiatric symptoms will be measured using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog).
Lower scores will indicate reduced cognitive impairment.
|
Baseline (before intervention) and after 6 months of intervention.
|
|
Change in Depression Levels (SDS Score)
Time Frame: Baseline (before intervention) and after 6 months of intervention.
|
Depression levels will be measured using the Self-Rating Depression Scale (SDS).
The SDS score ranges from 25 to 100, with higher scores indicating greater depression severity.
A reduction in scores post-intervention will indicate an improvement in depression symptoms.
|
Baseline (before intervention) and after 6 months of intervention.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023199
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Xuanwu Hospital, BeijingEnrolling by invitation
-
Beijing Tiantan HospitalNot yet recruiting
-
Danyang Huichuang Medical Equipment Co., Ltd.RecruitingAlzheimer s DiseaseChina
Clinical Trials on Holistic Nursing
-
The University of Texas Health Science Center at...Completed
-
Fatima Jinnah Women UniversityNot yet recruitingType 2 Diabetes Risk Reduction in Young AdultsPakistan
-
Goddess Zena I. JonesWithdrawnDepression | PTSD | Hypertension | Fatigue | Arthritis | Rheumatoid Arthritis | Migraine | Anemia | Hyperthyroidism | Anxiety | TBI (Traumatic Brain Injury) | Erectile Dysfunction | Sickle Cell Disease | Anemia, Sickle Cell | Priapism | Hemorrhoids | Immunodeficiency | Migraine With Aura | Fibroid | Sickle Cell Trait | Stress, Job | Sexual... and other conditionsUnited States
-
Virtual Tribunal MonasteryWithdrawnUterine Fibroids Affecting Pregnancy | Uterine Fibroids - 1St Diagnosis | Uterine Fibroid DegeneratedUnited States
-
Gazi UniversityCompleted
-
University of the PunjabCompleted
-
University of CalgaryCompleted
-
The University of Hong KongCompletedSelf-esteem | Family Relationship | Self-efficacyChina
-
The University of Hong KongThe Hong Kong Jockey Club Charties TrustCompletedQuality of Life | Physical Activity | Health BehaviorHong Kong
-
McMaster UniversityHAMSMaRT; Keeping Six; YWCA HamiltonNot yet recruitingInfections | Peer Support | Injection-related Infections | People Who Infect Drugs (PWID)Canada